Global Cancer Cachexia Market Report 2024

The cancer cachexia market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $ 2.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increasing aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.

The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, an expanding geriatric population, growing adoption of novel therapeutic approaches, increasing healthcare expenditure, and favorable government initiatives. Key trends expected in the forecast period include increased research and development efforts, expanding therapeutic options, improved diagnosis rates, the adoption of novel treatment modalities, and advancements in supportive care strategies.

The increasing prevalence of cancer is expected to drive the growth of the cancer cachexia market in the future. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells in the body, forming tumors and disrupting normal bodily functions. The rise in cancer cases can be attributed to factors such as lifestyle changes, environmental influences, an aging population, genetic predispositions, improved diagnostic methods leading to earlier detection, and increased awareness prompting more people to seek medical attention. Advances in medical technology and a better understanding of cancer and its complications are resulting in more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are becoming more adept at identifying cachexia symptoms, allowing for earlier interventions and treatment. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of the Australian population, or 456,200 individuals, had cancer in 2022. Additionally, in December 2021, the Australian Institute of Health and Welfare reported that around 151,000 Australians were diagnosed with cancer in 2021, equating to about 413 diagnoses per day. Thus, the rising prevalence of cancer is driving the growth of the cancer cachexia market.

Major companies in the cancer cachexia market are developing innovative medications, such as ghrelin receptor agonists, to address the debilitating symptoms and complications associated with cachexia, aiming to improve patient outcomes and quality of life. Ghrelin receptor agonists are medications that activate the ghrelin receptor in the body to treat cancer cachexia. For instance, in April 2021, Helsinn, a Swiss pharmaceutical company, launched Adlumiz (anamorelin) in Japan for treating cancer cachexia in various cancers. Adlumiz (anamorelin) is a ghrelin receptor agonist designed to treat cancer cachexia in several malignant tumors, including non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. Approved by Japanese health authorities, Adlumiz has demonstrated effectiveness in increasing body weight, muscle mass, and appetite in cancer cachexia patients. Anamorelin selectively stimulates pathways that positively regulate body weight, muscle mass, appetite, and metabolism. The anticipated benefits of Adlumiz outweigh its risks, offering a promising option for adult cancer patients experiencing cachexia symptoms.

In January 2023, LG Chem Ltd., a South Korean chemical company, acquired AVEO Oncology for an undisclosed amount. This acquisition aims to diversify LG Chem's product portfolio and enhance its capabilities in drug development, commercialization, and acquisitions, thereby accelerating its progress toward delivering cutting-edge cancer treatments. AVEO Oncology, a US-based biopharmaceutical company, provides a potential treatment for cancer cachexia.

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer cachexia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. This multifactorial condition arises from a combination of factors, including inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impair their ability to tolerate cancer treatments, and reduce overall survival.

The main therapeutics for cancer cachexia include progestogens, corticosteroids, combination therapies, and others. Progestogens, a type of medication often used in treating cancer cachexia, work by mimicking the effects of natural progesterone hormones in the body, potentially helping to increase appetite and muscle mass in patients. These treatments operate through various mechanisms, such as appetite stimulation and weight loss stabilization, and are distributed via hospital stores, retail pharmacies, and online pharmacies.

The cancer cachexia market research report is one of a series of new reports that provides cancer cachexia market statistics, including cancer cachexia industry global market size, regional shares, competitors with a cancer cachexia market share, detailed cancer cachexia market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cachexia industry. This cancer cachexia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer cachexia market consists of revenues earned by entities by providing services such as nutritional counseling, physical therapy, and exercise training. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cachexia market also includes sales of anabolic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral nutritional supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.